https://www.liebertpub.com/doi/10.1089/dia.2022.0248 Abstract Achieving glycemic targets in youth and young adults with type 1 diabetes is challenging. Diabetes devices including continuous…
Increasing evidence demonstrates the benefits of new diabetes technologies, including insulin pumps and continuous glucose monitors (CGM), for glycemic management…
Abstract Background Despite documented benefits of diabetes technology in managing type 1 diabetes, inequities persist in the use of…
Background An estimated 1.1 million children and adolescents aged under 20 years have type 1 diabetes worldwide. Principal investigators from seven…
Context The impact of the COVID-19 pandemic on individuals with type 1 diabetes remains poorly defined. Objective We examined United…
Background An increase in newly diagnosed type 1 diabetes (T1D) has been posited during the COVID-19 pandemic, but data are…
Background: Patient outcomes of COVID-19 have improved throughout the pandemic. However, because it is not known whether outcomes of COVID-19 in…
INTRODUCTION Approximately 1.6 million people in the United States have type 1 diabetes (T1D).1 The incidence of T1D is increasing in…
INTRODUCTION Since the discovery of insulin 100 years ago, there have been continual advances in medications and technologies for the management…
Objective The prevalence of depression among adolescents with type 1 diabetes is estimated to be 2–3 times higher than in…